Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All montelukast studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients

Camera et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.784214
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
28th treatment shown to reduce risk in November 2021
 
*, now with p = 0.0045 from 8 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
In Vitro study showing that montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Authors demonstrate that montelukast prevents the surface expression of tissue factor (TF) and P-selectin on platelets, reduces the formation of circulating monocyte- and granulocyte-platelet aggregates, and completely inhibits the release of TF-positive circulating microvesicles. Exogenous LTE4, at concentrations comparable to those in bronchoalveolar lavage of COVID-19 patients, induced expression of TF and P-selectin on platelets.
Camera et al., 8 Feb 2022, retrospective, Italy, peer-reviewed, 4 authors. Contact: genrico.rovati@unimi.it.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperMontelukastAll
Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients
Marina Camera, Paola Canzano, Marta Brambilla, G Enrico Rovati
Frontiers in Pharmacology, doi:10.3389/fphar.2022.784214
Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely LTC 4 , LTD 4 , and LTE 4 are involved in many of the principal features of asthma, while more recently they have also been implicated in cardiovascular diseases. COVID-19 is characterized by an overwhelming state of inflammation, sometimes resulting in an acute respiratory distress syndrome. Furthermore, severe COVID-19 patients present an endothelial cell damage characterized by a hyperinflammatory/procoagulant state and a widespread thrombotic disease. Leukotriene receptor antagonists, such as montelukast, have long been proven to have an efficacy in asthma, while more recently they have been suggested to have a protective role also in cardiovascular diseases. As elevated levels of LTE 4 have been detected in bronchoalveolar lavage of COVID-19 patients, and montelukast, in addition to its anti-inflammatory properties, has been suggested to have a protective role in cardiovascular diseases, we decided to investigate whether this drug could also affect the platelet activation characteristic of COVID-19 syndrome. In this contribution, we demonstrate that montelukast inhibits platelet activation induced by plasma from COVID-19 patients by preventing the surface expression of tissue factor (TF) and P-selectin, reducing the formation of circulating monocyte-and granulocyte-platelet aggregates, and, finally, in completely inhibiting the release of TF pos -circulating microvesicles. These data suggest the repurposing of montelukast as a possible auxiliary treatment for COVID-19 syndrome.
ETHICS STATEMENT The studies involving human participants were reviewed and approved by the Ethical Committee of the institution (number 2020_06_16_18). The patients/participants provided their written informed consent to participate in this study. AUTHOR CONTRIBUTIONS MC: helped in designing the study and was a major contributor in the discussion of results and the writing of the manuscript. PC and MB: performed the experiments and participated in writing the manuscript. GR: conceived the study and was a major contributor in the discussion of the data and in the writing of the manuscript. SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.784214/ full#supplementary-material Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ackermann, Verleden, Kuehnel, Haverich, Welte et al., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2015432
Aigner, Pietrantonio, Bessa De Sousa, Michael, Schuster et al., The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic, Front. Mol. Biosci, doi:10.3389/fmolb.2020.610132
Archambault, Zaid, Rakotoarivelo, Turcotte, Doré et al., High Levels of Eicosanoids and Docosanoids in the Lungs of Intubated COVID-19 Patients, FASEB J, doi:10.1096/fj.202100540R
Arnardottir, Pawelzik, Öhlund Wistbacka, Artiach, Hofmann et al., Stimulating the Resolution of Inflammation through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial, Front. Physiol, doi:10.3389/fphys.2020.624657
Austen, Maekawa, Kanaoka, Boyce, The Leukotriene E(4) Puzzle: Finding the Missing Pieces and Revealing the Pathobiologic Implications, J. Allergy Clin. Immunol, doi:10.1016/j.jaci.2009.05.046
Barré, Sabatier, Annweiler, Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence, Front. Pharmacol, doi:10.3389/fphar.2020.01344
Bozek, Winterstein, Montelukast's Ability to Fight COVID-19 Infection, J. Asthma, doi:10.1080/02770903.2020.1786112
Bäck, Powell, Dahlén, Drazen, Evans et al., Update on Leukotriene, Lipoxin and Oxoeicosanoid Receptors: IUPHAR Review 7, Br. J. Pharmacol, doi:10.1111/bph.12665
Bäck, Yurdagul, Tabas, Öörni, Kovanen, Inflammation and its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities, Nat. Rev. Cardiol, doi:10.1038/s41569-019-0169-2
Canzano, Brambilla, Porro, Cosentino, Tortorici et al., Platelet and Endothelial Activation as Potential Mechanisms behind the Thrombotic Complications of COVID-19 Patients, JACC: Basic Translational Sci, doi:10.1016/j.jacbts.2020.12.009
Capra, Ambrosio, Riccioni, Rovati, Cysteinyl-leukotriene Receptor Antagonists: Present Situation and Future Opportunities, Curr. Med. Chem, doi:10.2174/092986706778742963
Capra, Bäck, Barbieri, Camera, Tremoli et al., Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke, Med. Res. Rev, doi:10.1002/med.21251
Chen, Hoiland, Stukas, Wellington, Sekhon, Confronting the Controversy: Interleukin-6 and the COVID-19 Cytokine Storm Syndrome, Eur. Respir. J, doi:10.1183/13993003.03006-2020
England, Abdulla, Biggs, Lee, Hay et al., Weathering the COVID-19 Storm: Lessons from Hematologic Cytokine Syndromes, Blood Rev, doi:10.1016/j.blre.2020.100707
Foster, Fuerst, Lee, Cousins, Woszczek, Characterisation of P2Y(12) Receptor Responsiveness to Cysteinyl Leukotrienes, PLoS One, doi:10.1371/journal.pone.0058305PONE-D-12-35349
Funk, Ardakani, A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes, Front. Pharmacol, doi:10.3389/fphar.2020.01214
Funk, Leukotriene Modifiers as Potential Therapeutics for Cardiovascular Disease, Nat. Rev. Drug Discov, doi:10.1038/nrd1796
Haeggström, Funk, Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease, Chem. Rev, doi:10.1021/cr200246d
Hammock, Wang, Gilligan, Panigrahy, Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?, Am. J. Pathol, doi:10.1016/j.ajpath.2020.06.010
Hasegawa, Ichiyama, Hashimoto, Suzuki, Hirano et al., Functional Expression of Cysteinyl Leukotriene Receptors on Human Platelets, Platelets, doi:10.3109/09537101003615394
Heavey, Soberman, Lewis, Spur, Critical Considerations in the Development of an Assay for Sulfidopeptide Leukotrienes in Plasma, Prostaglandins, doi:10.1016/0090-6980(87)90035-9
Hoxha, Rovati, Cavanillas, The Leukotriene Receptor Antagonist Montelukast and its Possible Role in the Cardiovascular Field, Eur. J. Clin. Pharmacol, doi:10.1007/s00228-017-2242-2
Hoxha, Tedesco, Quaglin, Malaj, Pustina et al., Montelukast Use Decreases Cardiovascular Events in Asthmatics, Front. Pharmacol, doi:10.3389/fphar.2020.611561
Ingelsson, Yin, Bäck, Nationwide Cohort Study of the Leukotriene Receptor Antagonist Montelukast and Incident or Recurrent Cardiovascular Disease, J. Allergy Clin. Immunol, doi:10.1016/j.jaci.2011.11.052
Khan, Misdary, Yegya-Raman, Kim, Narayanan et al., Montelukast in Hospitalized Patients Diagnosed with COVID-19, J. Asthma, doi:10.1080/02770903.2021.1881967
Maeba, Ichiyama, Ueno, Makata, Matsubara et al., Effect of Montelukast on Nuclear Factor kappaB Activation and Proinflammatory Molecules, Ann. Allergy Asthma Immunol, doi:10.1016/S1081-1206(10)61326-9
Mamedova, Capra, Accomazzo, Gao, Ferrario et al., CysLT1 Leukotriene Receptor Antagonists Inhibit the Effects of Nucleotides Acting at P2Y Receptors, Biochem. Pharmacol, doi:10.1016/j.bcp.2005.10.003
Marchandot, Curtiaud, Trimaille, Sattler, Grunebaum et al., Vaccine-induced Immune Thrombotic Thrombocytopenia: Current Evidence, Potential Mechanisms, Clinical Implications, and Future Directions, Eur. Hear. J. Open, doi:10.1093/ehjopen/oeab014
Nishiga, Wang, Han, Lewis, Wu, COVID-19 and Cardiovascular Disease: from Basic Mechanisms to Clinical Perspectives, Nat. Rev. Cardiol, doi:10.1038/s41569-020-0413-9
Sala, Murphy, Voelkel, Sanghai, Tranmer, Taming the Cytokine Storm: Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms, Drug Discov. Today, doi:10.1016/j.drudis.2020.09.013
Sokolowska, Rovati, Diamant, Untersmayr, Schwarze et al., Current Perspective on Eicosanoids in Asthma and Allergic Diseases: EAACI Task Force Consensus Report, Part I. Allergy, doi:10.1111/all.14295
Tahan, Jazrawi, Moodley, Rovati, Adcock, Montelukast Inhibits Tumour Necrosis Factor-Alpha-Mediated Interleukin-8 Expression through Inhibition of Nuclear Factor-kappaB P65-Associated Histone Acetyltransferase Activity, Clin. Exp. Allergy, doi:10.1111/j.1365-2222.2008.02963.x
Taus, Salvagno, Canè, Fava, Mazzaferri et al., Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia, Arterioscler. Thromb. Vasc. Biol, doi:10.1161/ATVBAHA.120.315175
Teuwen, Geldhof, Pasut, Carmeliet, COVID-19: the Vasculature Unleashed, Nat. Rev. Immunol, doi:10.1038/s41577-020-0343-0
Trinh, Lee, Cao, Park, Asthma Pharmacotherapy: an Update on Leukotriene Treatments, Expert Rev. Respir. Med, doi:10.1080/17476348.2019.1670640
Virchow, Bachert, Efficacy and Safety of Montelukast in Adults with Asthma and Allergic Rhinitis, Respir. Med, doi:10.1016/j.rmed.2006.02.026
Woszczek, Chen, Alsaaty, Nagineni, Shelhamer, Concentration-dependent Noncysteinyl Leukotriene Type 1 Receptor-Mediated Inhibitory Activity of Leukotriene Receptor Antagonists, J. Immunol, doi:10.4049/jimmunol.0900071
Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
{ 'indexed': { 'date-parts': [[2023, 10, 24]], 'date-time': '2023-10-24T17:43:02Z', 'timestamp': 1698169382577}, 'reference-count': 39, 'publisher': 'Frontiers Media SA', 'license': [ { 'start': { 'date-parts': [[2022, 2, 8]], 'date-time': '2022-02-08T00:00:00Z', 'timestamp': 1644278400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': ['frontiersin.org'], 'crossmark-restriction': True}, 'abstract': '<jats:p>Leukotrienes are important pro-inflammatory lipid mediators derived from the ' 'arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely ' 'LTC<jats:sub>4</jats:sub>, LTD<jats:sub>4</jats:sub>, and LTE<jats:sub>4</jats:sub> are ' 'involved in many of the principal features of asthma, while more recently they have also been ' 'implicated in cardiovascular diseases. COVID-19 is characterized by an overwhelming state of ' 'inflammation, sometimes resulting in an acute respiratory distress syndrome. Furthermore, ' 'severe COVID-19 patients present an endothelial cell damage characterized by a ' 'hyperinflammatory/procoagulant state and a widespread thrombotic disease. Leukotriene ' 'receptor antagonists, such as montelukast, have long been proven to have an efficacy in ' 'asthma, while more recently they have been suggested to have a protective role also in ' 'cardiovascular diseases. As elevated levels of LTE<jats:sub>4</jats:sub> have been detected ' 'in bronchoalveolar lavage of COVID-19 patients, and montelukast, in addition to its ' 'anti-inflammatory properties, has been suggested to have a protective role in cardiovascular ' 'diseases, we decided to investigate whether this drug could also affect the platelet ' 'activation characteristic of COVID-19 syndrome. In this contribution, we demonstrate that ' 'montelukast inhibits platelet activation induced by plasma from COVID-19 patients by ' 'preventing the surface expression of tissue factor (TF) and P-selectin, reducing the ' 'formation of circulating monocyte– and granulocyte–platelet aggregates, and, finally, in ' 'completely inhibiting the release of TF<jats:sup>pos</jats:sup>-circulating microvesicles. ' 'These data suggest the repurposing of montelukast as a possible auxiliary treatment for ' 'COVID-19 syndrome.</jats:p>', 'DOI': '10.3389/fphar.2022.784214', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 8]], 'date-time': '2022-02-08T07:07:10Z', 'timestamp': 1644304030000}, 'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy', 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': 'Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients', 'prefix': '10.3389', 'volume': '13', 'author': [ {'given': 'Marina', 'family': 'Camera', 'sequence': 'first', 'affiliation': []}, {'given': 'Paola', 'family': 'Canzano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marta', 'family': 'Brambilla', 'sequence': 'additional', 'affiliation': []}, {'given': 'G. Enrico', 'family': 'Rovati', 'sequence': 'additional', 'affiliation': []}], 'member': '1965', 'published-online': {'date-parts': [[2022, 2, 8]]}, 'reference': [ { 'key': 'B1', 'doi-asserted-by': 'publisher', 'first-page': '120', 'DOI': '10.1056/NEJMoa2015432', 'article-title': 'Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in ' 'Covid-19', 'volume': '383', 'author': 'Ackermann', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'B2', 'doi-asserted-by': 'publisher', 'first-page': '610132', 'DOI': '10.3389/fmolb.2020.610132', 'article-title': 'The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 ' 'Therapeutic', 'volume': '7', 'author': 'Aigner', 'year': '2020', 'journal-title': 'Front. Mol. Biosci.'}, { 'key': 'B3', 'doi-asserted-by': 'publisher', 'first-page': 'e21666', 'DOI': '10.1096/fj.202100540R', 'article-title': 'High Levels of Eicosanoids and Docosanoids in the Lungs of Intubated ' 'COVID-19 Patients', 'volume': '35', 'author': 'Archambault', 'year': '2021', 'journal-title': 'FASEB J.'}, { 'key': 'B4', 'doi-asserted-by': 'publisher', 'first-page': '624657', 'DOI': '10.3389/fphys.2020.624657', 'article-title': 'Stimulating the Resolution of Inflammation through Omega-3 ' 'Polyunsaturated Fatty Acids in COVID-19: Rationale for the ' 'COVID-Omega-F Trial', 'volume': '11', 'author': 'Arnardottir', 'year': '2020', 'journal-title': 'Front. Physiol.'}, { 'key': 'B5', 'doi-asserted-by': 'publisher', 'first-page': '406', 'DOI': '10.1016/j.jaci.2009.05.046', 'article-title': 'The Leukotriene E(4) Puzzle: Finding the Missing Pieces and Revealing ' 'the Pathobiologic Implications', 'volume': '124', 'author': 'Austen', 'year': '2009', 'journal-title': 'J. Allergy Clin. Immunol.'}, { 'key': 'B6', 'doi-asserted-by': 'publisher', 'first-page': '3551', 'DOI': '10.1111/bph.12665', 'article-title': 'Update on Leukotriene, Lipoxin and Oxoeicosanoid Receptors: IUPHAR ' 'Review 7', 'volume': '171', 'author': 'Bäck', 'year': '2014', 'journal-title': 'Br. J. Pharmacol.'}, { 'key': 'B7', 'doi-asserted-by': 'publisher', 'first-page': '389', 'DOI': '10.1038/s41569-019-0169-2', 'article-title': 'Inflammation and its Resolution in Atherosclerosis: Mediators and ' 'Therapeutic Opportunities', 'volume': '16', 'author': 'Bäck', 'year': '2019', 'journal-title': 'Nat. Rev. Cardiol.'}, { 'key': 'B8', 'doi-asserted-by': 'publisher', 'first-page': '1344', 'DOI': '10.3389/fphar.2020.01344', 'article-title': 'Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence', 'volume': '11', 'author': 'Barré', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B9', 'doi-asserted-by': 'publisher', 'first-page': '1348', 'DOI': '10.1080/02770903.2020.1786112', 'article-title': "Montelukast's Ability to Fight COVID-19 Infection", 'volume': '58', 'author': 'Bozek', 'year': '2020', 'journal-title': 'J. Asthma'}, { 'key': 'B10', 'doi-asserted-by': 'publisher', 'first-page': '202', 'DOI': '10.1016/j.jacbts.2020.12.009', 'article-title': 'Platelet and Endothelial Activation as Potential Mechanisms behind the ' 'Thrombotic Complications of COVID-19 Patients', 'volume': '6', 'author': 'Canzano', 'year': '2021', 'journal-title': 'JACC: Basic Translational Sci.'}, { 'key': 'B11', 'doi-asserted-by': 'publisher', 'first-page': '3213', 'DOI': '10.2174/092986706778742963', 'article-title': 'Cysteinyl-leukotriene Receptor Antagonists: Present Situation and ' 'Future Opportunities', 'volume': '13', 'author': 'Capra', 'year': '2006', 'journal-title': 'Curr. Med. Chem.'}, { 'key': 'B12', 'doi-asserted-by': 'publisher', 'first-page': '364', 'DOI': '10.1002/med.21251', 'article-title': 'Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on ' 'Atherosclerosis and Stroke', 'volume': '33', 'author': 'Capra', 'year': '2013', 'journal-title': 'Med. Res. Rev.'}, { 'key': 'B13', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/13993003.03006-2020', 'article-title': 'Confronting the Controversy: Interleukin-6 and the COVID-19 Cytokine ' 'Storm Syndrome', 'volume': '56', 'author': 'Chen', 'year': '2020', 'journal-title': 'Eur. Respir. J.'}, { 'key': 'B14', 'doi-asserted-by': 'publisher', 'first-page': '100707', 'DOI': '10.1016/j.blre.2020.100707', 'article-title': 'Weathering the COVID-19 Storm: Lessons from Hematologic Cytokine ' 'Syndromes', 'volume': '45', 'author': 'England', 'year': '2021', 'journal-title': 'Blood Rev.'}, { 'key': 'B15', 'doi-asserted-by': 'publisher', 'first-page': 'e58305', 'DOI': '10.1371/journal.pone.0058305PONE-D-12-35349', 'article-title': 'Characterisation of P2Y(12) Receptor Responsiveness to Cysteinyl ' 'Leukotrienes', 'volume': '8', 'author': 'Foster', 'year': '2013', 'journal-title': 'PLoS One'}, { 'key': 'B16', 'doi-asserted-by': 'publisher', 'first-page': '1214', 'DOI': '10.3389/fphar.2020.01214', 'article-title': 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 ' 'by Targeting Leukotrienes', 'volume': '11', 'author': 'Funk', 'year': '2020', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B17', 'doi-asserted-by': 'publisher', 'first-page': '664', 'DOI': '10.1038/nrd1796', 'article-title': 'Leukotriene Modifiers as Potential Therapeutics for Cardiovascular ' 'Disease', 'volume': '4', 'author': 'Funk', 'year': '2005', 'journal-title': 'Nat. Rev. Drug Discov.'}, { 'key': 'B18', 'doi-asserted-by': 'publisher', 'first-page': '5866', 'DOI': '10.1021/cr200246d', 'article-title': 'Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles ' 'in Disease', 'volume': '111', 'author': 'Haeggström', 'year': '2011', 'journal-title': 'Chem. Rev.'}, { 'key': 'B19', 'doi-asserted-by': 'publisher', 'first-page': '1782', 'DOI': '10.1016/j.ajpath.2020.06.010', 'article-title': 'Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 ' '(COVID-19)?', 'volume': '190', 'author': 'Hammock', 'year': '2020', 'journal-title': 'Am. J. Pathol.'}, { 'key': 'B20', 'doi-asserted-by': 'publisher', 'first-page': '253', 'DOI': '10.3109/09537101003615394', 'article-title': 'Functional Expression of Cysteinyl Leukotriene Receptors on Human ' 'Platelets', 'volume': '21', 'author': 'Hasegawa', 'year': '2010', 'journal-title': 'Platelets'}, { 'key': 'B21', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1016/0090-6980(87)90035-9', 'article-title': 'Critical Considerations in the Development of an Assay for ' 'Sulfidopeptide Leukotrienes in Plasma', 'volume': '33', 'author': 'Heavey', 'year': '1987', 'journal-title': 'Prostaglandins'}, { 'key': 'B22', 'doi-asserted-by': 'publisher', 'first-page': '799', 'DOI': '10.1007/s00228-017-2242-2', 'article-title': 'The Leukotriene Receptor Antagonist Montelukast and its Possible Role ' 'in the Cardiovascular Field', 'volume': '73', 'author': 'Hoxha', 'year': '2017', 'journal-title': 'Eur. J. Clin. Pharmacol.'}, { 'key': 'B23', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2020.611561', 'article-title': 'Montelukast Use Decreases Cardiovascular Events in Asthmatics', 'volume': '11', 'author': 'Hoxha', 'year': '2021', 'journal-title': 'Front. Pharmacol.'}, { 'key': 'B24', 'doi-asserted-by': 'publisher', 'first-page': '702', 'DOI': '10.1016/j.jaci.2011.11.052', 'article-title': 'Nationwide Cohort Study of the Leukotriene Receptor Antagonist ' 'Montelukast and Incident or Recurrent Cardiovascular Disease', 'volume': '129', 'author': 'Ingelsson', 'year': '2012', 'journal-title': 'J. Allergy Clin. Immunol.'}, { 'key': 'B25', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1080/02770903.2021.1881967', 'article-title': 'Montelukast in Hospitalized Patients Diagnosed with COVID-19', 'author': 'Khan', 'year': '2021', 'journal-title': 'J. Asthma'}, { 'key': 'B26', 'doi-asserted-by': 'publisher', 'first-page': '670', 'DOI': '10.1016/S1081-1206(10)61326-9', 'article-title': 'Effect of Montelukast on Nuclear Factor kappaB Activation and ' 'Proinflammatory Molecules', 'volume': '94', 'author': 'Maeba', 'year': '2005', 'journal-title': 'Ann. Allergy Asthma Immunol.'}, { 'key': 'B27', 'doi-asserted-by': 'publisher', 'first-page': '115', 'DOI': '10.1016/j.bcp.2005.10.003', 'article-title': 'CysLT1 Leukotriene Receptor Antagonists Inhibit the Effects of ' 'Nucleotides Acting at P2Y Receptors', 'volume': '71', 'author': 'Mamedova', 'year': '2005', 'journal-title': 'Biochem. Pharmacol.'}, { 'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ehjopen/oeab014', 'article-title': 'Vaccine-induced Immune Thrombotic Thrombocytopenia: Current Evidence, ' 'Potential Mechanisms, Clinical Implications, and Future Directions', 'volume': '1', 'author': 'Marchandot', 'year': '2021', 'journal-title': 'Eur. Hear. J. Open'}, { 'key': 'B29', 'doi-asserted-by': 'publisher', 'first-page': '543', 'DOI': '10.1038/s41569-020-0413-9', 'article-title': 'COVID-19 and Cardiovascular Disease: from Basic Mechanisms to Clinical ' 'Perspectives', 'volume': '17', 'author': 'Nishiga', 'year': '2020', 'journal-title': 'Nat. Rev. Cardiol.'}, { 'key': 'B30', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/0090-6980(91)90088-W', 'article-title': 'Direct Airway Injury Results in Elevated Levels of Sulfidopeptide ' 'Leukotrienes, Detectable in Airway Secretions', 'volume': '42', 'author': 'Sala', 'year': '1991', 'journal-title': 'Prostaglandins'}, { 'key': 'B31', 'doi-asserted-by': 'publisher', 'first-page': '2076', 'DOI': '10.1016/j.drudis.2020.09.013', 'article-title': 'Taming the Cytokine Storm: Repurposing Montelukast for the Attenuation ' 'and Prophylaxis of Severe COVID-19 Symptoms', 'volume': '25', 'author': 'Sanghai', 'year': '2020', 'journal-title': 'Drug Discov. Today'}, { 'key': 'B32', 'doi-asserted-by': 'publisher', 'first-page': '114', 'DOI': '10.1111/all.14295', 'article-title': 'Current Perspective on Eicosanoids in Asthma and Allergic Diseases: ' 'EAACI Task Force Consensus Report, Part I', 'volume': '76', 'author': 'Sokolowska', 'year': '2021', 'journal-title': 'Allergy'}, { 'key': 'B33', 'doi-asserted-by': 'publisher', 'first-page': '805', 'DOI': '10.1111/j.1365-2222.2008.02963.x', 'article-title': 'Montelukast Inhibits Tumour Necrosis Factor-Alpha-Mediated ' 'Interleukin-8 Expression through Inhibition of Nuclear Factor-kappaB ' 'P65-Associated Histone Acetyltransferase Activity', 'volume': '38', 'author': 'Tahan', 'year': '2008', 'journal-title': 'Clin. Exp. Allergy'}, { 'key': 'B34', 'doi-asserted-by': 'publisher', 'first-page': '2975', 'DOI': '10.1161/ATVBAHA.120.315175', 'article-title': 'Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia', 'volume': '40', 'author': 'Taus', 'year': '2020', 'journal-title': 'Arterioscler. Thromb. Vasc. Biol.'}, { 'key': 'B35', 'doi-asserted-by': 'publisher', 'first-page': '389', 'DOI': '10.1038/s41577-020-0343-0', 'article-title': 'COVID-19: the Vasculature Unleashed', 'volume': '20', 'author': 'Teuwen', 'year': '2020', 'journal-title': 'Nat. Rev. Immunol.'}, { 'key': 'B36', 'doi-asserted-by': 'publisher', 'first-page': '1169', 'DOI': '10.1080/17476348.2019.1670640', 'article-title': 'Asthma Pharmacotherapy: an Update on Leukotriene Treatments', 'volume': '13', 'author': 'Trinh', 'year': '2019', 'journal-title': 'Expert Rev. Respir. Med.'}, { 'key': 'B37', 'doi-asserted-by': 'publisher', 'first-page': '1952', 'DOI': '10.1016/j.rmed.2006.02.026', 'article-title': 'Efficacy and Safety of Montelukast in Adults with Asthma and Allergic ' 'Rhinitis', 'volume': '100', 'author': 'Virchow', 'year': '2006', 'journal-title': 'Respir. Med.'}, { 'key': 'B38', 'doi-asserted-by': 'publisher', 'first-page': '2219', 'DOI': '10.4049/jimmunol.0900071', 'article-title': 'Concentration-dependent Noncysteinyl Leukotriene Type 1 ' 'Receptor-Mediated Inhibitory Activity of Leukotriene Receptor ' 'Antagonists', 'volume': '184', 'author': 'Woszczek', 'year': '2010', 'journal-title': 'J. Immunol.'}, { 'key': 'B39', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and Important Lessons from the Coronavirus Disease ' '2019 (COVID-19) Outbreak in China: Summary of a Report of 72\u202f314 ' 'Cases from the Chinese Center for Disease Control and Prevention', 'volume': '323', 'author': 'Wu', 'year': '2020', 'journal-title': 'JAMA'}], 'container-title': 'Frontiers in Pharmacology', 'original-title': [], 'link': [ { 'URL': 'https://www.frontiersin.org/articles/10.3389/fphar.2022.784214/full', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 8]], 'date-time': '2022-02-08T07:07:12Z', 'timestamp': 1644304032000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.frontiersin.org/articles/10.3389/fphar.2022.784214/full'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2, 8]]}, 'references-count': 39, 'alternative-id': ['10.3389/fphar.2022.784214'], 'URL': 'http://dx.doi.org/10.3389/fphar.2022.784214', 'relation': {}, 'ISSN': ['1663-9812'], 'subject': [], 'container-title-short': 'Front. Pharmacol.', 'published': {'date-parts': [[2022, 2, 8]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit